GOVX-B11 HIV Vaccine Description
GOVX-B11 is a Clade B HIV vaccine candidate that uses recombinant DNA and recombinant modified vaccinia Ankara (MVA) vaccines to express non-infectious virus-like particles.
The GOVX-B11 vaccine consists of a recombinant DNA vaccine used to prime immune responses and a recombinant MVA vaccine used to boost the primed responses.
GOVX-B11 HIV Vaccine Indication
GOVX-B11 is indicated to prevent HIV disease
GOVX-B11 HIV Vaccine Dosage
The proposed regimen for the Phase 2b efficacy trial consists of DNA delivered into the muscle with a needle and syringe at 0 and 2 months and MVA delivered into the muscle with a needle and syringe at 4, 6, and 10 months (DDMM_M regimen).
GOVX-B11 HIV Vaccine News
August 10, 2020 - The development of GeoVax’s preventive HIV vaccine (GOVX-B11) from preclinical studies to human clinical trials has been supported by funding from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Following human studies by the HIV Vaccine Trials Network (HVTN) with support from NIAID, the Company is now planning for a new Phase 1 human clinical trial (designated HVTN 132) to further assess the safety, tolerability, and immunogenicity (elicited antibody responses) of a prime-boost regimen of GOVX-B11 in combination with protein boost vaccines. Management has expected that HVTN 132 would commence patient enrollment in late 2020 but now anticipates the trial to start during the first half of 2021 due to the trial sites being utilized for COVID-19 vaccine testing.
November 28, 2018 - GeoVax Labs, Inc. provided an update of the clinical development plan for its preventive vaccine (GOVX-B11) for clade B HIV. The HIV Vaccine Trials Network (HVTN) is moving forward with plans for a phase 1 trial, designated HVTN 132, which will be a multi-center, randomized, double-blind trial, enrolling up to 70 healthy adults. The primary objectives of the trial will be to assess the safety, tolerability, and immunogenicity (elicited antibody responses) of a prime-boost regimen of GOVX-B11, in combination with protein boosts. HVTN 132 is expected to commence patient enrollment in mid-2019.